Fluvastatin Versus Hepatitis C Virus

A Dose Finding Study of Fluvastatin for in Vivo Demonstration of Inhibiting Hepatitis C Replication in Patients Infected With Chronic Hepatitis C With Special Attention to the African-American Population.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00441493

Enrollment

Registered

2007-03-01

Start date

2006-09-30

Completion date

2007-09-30

Last updated

2012-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Keywords

Hepatitis C, fluvastatin

Brief summary

This is a dose finding and efficacy trial for fluvastatin versus hepatitis C.

Detailed description

Four different oral doses of fluvastatin will be used for 14 days and the viral load of hepatitis C will be measured weekly. This has been extended to different doses for 9-12 weeks.

Interventions

DRUGfluvastatin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* HCV RNA positive

Exclusion criteria

* Testing positive for alcohol or marijuana

Design outcomes

Primary

Measure	Time frame
Viral Load Reduction, Liver test changes	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026